Celyad Oncology SA: Celyad Oncology Reports Full Year 2021 F

Phase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical activity in relapsed/refractory multiple myeloma (r/r MM)

Related Keywords

Brussels , Bruxelles Capitale , Belgium , United States , Mont Saint Guibert , Waals Gewest , New York , Walloon Region , Kenilworth , Paris , France General , France , Lincoln Park , American , Sara Zelkovic , Filippo Petti , Communications Investor Relations , Lifesci Advisors , Society For Immunotherapy Of Cancer , Fortress Investment Group , Belgian Institute For Health Insurance Inami , American Society Of Hematology , Lincoln Park Capital Fund , Exchange Commission , Merck Co Inc , Us Food Drug Administration , Euronext Nasdaq , Celyad Oncology , Chief Executive Officer , American Society , Annual Meeting , Metastatic Colorectal Cancer , Drug Administration , Acute Myeloid Leukemia , Myelodysplastic Syndrome , Federal Belgian Institute , Health Insurance Inami , Annual Report , Private Securities Litigation Reform Act , Equity Holders , Media Contacts , Investor Relations Director , Sci Advisors , Celyad , Ncology , Reports , Bull , Ear , 021 , Financial , Results , Ecent , Business , Highlights ,